A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial?
Abstract
Dehydroepiandrosterone (DHEA) and its sulfate ester are the most abundant steroids in humans. DHEA levels fall with age in men and women, reaching values sometimes as low as 10%–20% of those encountered in young individuals. This age-related decrease suggests an “adrenopause” phenomenon. Studies point toward several potential roles of DHEA, mainly through its hormonal end products, making this decline clinically relevant. Unfortunately, even if positive effects of DHEA on muscle, bone, cardiovascular disease, and sexual function seem rather robust, extremely few studies are large enough and/or long enough for conclusions regarding its effects on aging. Moreover, because it has been publically presented as a “fountain of youth” equivalent, over-the-counter preparations lacking pharmacokinetic and pharmacodynamic data are widely used worldwide. Conceptually, supplementing a pre-hormone is extremely interesting, because it would permit the human organism to adequately use it throughout long periods, increasing or decreasing end products according to his needs. Nevertheless, data on the safety profile of long-term DHEA supplementation are still lacking. In this article, we examine the potential relation between low DHEA levels and well-known age-related diseases, such as sarcopenia, osteoporosis, dementia, sexual disorders, and cardiovascular disease. We also review risks and benefits of existing protocols of DHEA supplementation.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Davis SRPanjari MStanczyk FZ. Clinical review: DHEA replacement for postmenopausal womenJ Clin Endocrinol Metab2011961642-1653. 1. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642–1653.
2.
Panjari MDavis SR. DHEA for postmenopausal women: A review of the evidenceMaturitas201066172-179. 2. Panjari M, Davis SR. DHEA for postmenopausal women: A review of the evidence. Maturitas 2010;66:172–179.
3.
Zouboulis CCChen WCThornton MJQin KRosenfield R. Sexual hormones in human skinHorm Metab Res2007Feb3985-95. 3. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007 Feb;39:85–95.
4.
Panjari MDavis SR. DHEA therapy for women: Effect on sexual function and wellbeingHum Reprod Update200713239-248. 4. Panjari M, Davis SR. DHEA therapy for women: Effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239–248.
5.
Legrain SMassien CLahlou NRoger MDebuire BDiquet BChatellier GAzizi MFaucounau VPorchet HForette FBaulieu EE. Dehydroepiandrosterone replacement administration: Pharmacokinetic and pharmacodynamic studies in healthy elderly subjectsJ Clin Endocrinol Metab2000853208-3217. 5. Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, Chatellier G, Azizi M, Faucounau V, Porchet H, Forette F, Baulieu EE. Dehydroepiandrosterone replacement administration: Pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab 2000;85:3208–3217.
6.
Genazzani ADLanzoni CGenazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly?Drugs Aging200724173-185. 6. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging 2007;24:173–185.
7.
Kushnir MMBlamires TRockwood ALRoberts WLYue BErdogan EBunker AMMeikle AW. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervalsClin Chem2010561138-1147. 7. Kushnir MM, Blamires T, Rockwood AL, Roberts WL, Yue B, Erdogan E, Bunker AM, Meikle AW. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem 2010;56:1138–1147.
8.
Kaufman JMVermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implicationsEndocr Rev200526833-876. 8. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833–876.
9.
Baulieu EEThomas GLegrain SLahlou NRoger MDebuire BFaucounau VGirard LHervy MPLatour FLeaud MCMokrane APitti-Ferrandi HTrivalle Cde Lacharrière ONouveau SRakoto-Arison BSouberbielle JCRaison JLe Bouc YRaynaud AGirerd XForette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issueProc Natl Acad Sci USA2000974279-4284. 9. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279–4284.
10.
Lebrun CEvan der Schouw YTde Jong FHPols HAGrobbee DELamberts SW. Relations between body composition, functional and hormonal parameters and quality of life in healthy postmenopausal womenMaturitas20065582-92. 10. Lebrun CE, van der Schouw YT, de Jong FH, Pols HA, Grobbee DE, Lamberts SW. Relations between body composition, functional and hormonal parameters and quality of life in healthy postmenopausal women. Maturitas 2006;55:82–92.
11.
Morales AJHaubrich RHHwang JYAsakura HYen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and womenClin Endocrinol199849421-432. 11. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49:421–432.
12.
Arlt WJustl HGCallies FReincke MHübler DOettel MErnst MSchulte HMAllolio B. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppressionJ Clin Endocrinol Metab1998831928-1934. 12. Arlt W, Justl HG, Callies F, Reincke M, Hübler D, Oettel M, Ernst M, Schulte HM, Allolio B. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998;83:1928–1934.
13.
Arlt WHaas JCallies FReincke MHübler DOettel MErnst MSchulte HMAllolio B. Biotransformation of oral dehydroepiandrosterone in elderly men: Significant increase in circulating estrogensJ Clin Endocrinol Metab1999842170-2176. 13. Arlt W, Haas J, Callies F, Reincke M, Hübler D, Oettel M, Ernst M, Schulte HM, Allolio B. Biotransformation of oral dehydroepiandrosterone in elderly men: Significant increase in circulating estrogens. J Clin Endocrinol Metab 1999;84:2170–2176.
14.
Morales AJNolan JJNelson JCYen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing ageJ Clin Endocrinol Metab1994781360-1367. 14. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360–1367.
15.
Liu DDillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3)J Biol Chem200227721379-21388. 15. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 2002;277:21379–21388.
16.
Liu DDillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: Evidence for a cell surface receptorSteroids200469279-289. 16. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: Evidence for a cell surface receptor. Steroids 2004;69:279–289.
17.
Simoncini TMannella PFornari LVarone GCaruso AGenazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanismsEndocrinology20031443449-3455. 17. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003;144:3449–3455.
18.
Traish AMKang HPSaad FGuay AT. Dehydroepiandrosterone (DHEA) a precursor steroid or an active hormone in human physiologyJ Sex Med201182960-2982. 18. Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone (DHEA) a precursor steroid or an active hormone in human physiology. J Sex Med 2011;8:2960–2982.
19.
Sanders AB. Changing clinical practice in geriatric emergency medicineAcad Emerg Med199961189-1193. 19. Sanders AB. Changing clinical practice in geriatric emergency medicine. Acad Emerg Med 1999;6:1189–1193.
20.
Lippuner KJohansson HKanis JARizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and womenOsteoporos Int2009201131-1140. 20. Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 2009;20:1131–1140.
21.
Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls PreventionJ Am Geriatr Soc200149664-672. 21. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001;49:664–672.
22.
Janssen IRoss R. Linking age-related changes in skeletal muscle mass and composition with metabolism and diseaseJ Nutr Health Aging20059408-419. 22. Janssen I, Ross R. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. J Nutr Health Aging 2005;9:408–419.
23.
Yen SSMorales AJKhorram O. Replacement of DHEA in aging men and women. Potential remedial effectsAnn NY Acad Sci1995774128-142. 23. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects. Ann NY Acad Sci 1995;774:128–142.
24.
Valenti GDenti LMaggio MCeda GVolpato SBandinelli SCeresini GCappola AGuralnik JMFerrucci L. Effect of DHEAS on skeletal muscle over the life span: The InCHIANTI studyJ Gerontol Ser A, Biol Sci Med Sci200459466-472. 24. Valenti G, Denti L, Maggio M, Ceda G, Volpato S, Bandinelli S, Ceresini G, Cappola A, Guralnik JM, Ferrucci L. Effect of DHEAS on skeletal muscle over the life span: The InCHIANTI study. J Gerontol Ser A, Biol Sci Med Sci 2004;59:466–472.
25.
Kostka TArsac LMPatricot MCBerthouze SELacour JRBonnefoy M. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly peopleEur J Appl Physiol20008283-90. 25. Kostka T, Arsac LM, Patricot MC, Berthouze SE, Lacour JR, Bonnefoy M. Leg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly people. Eur J Appl Physiol 2000;82:83–90.
26.
Ravaglia GForti PMaioli FBoschi FCicognani ABernardi MPratelli LPizzoferrato APorcu SGasbarrini G. Determinants of functional status in healthy Italian nonagenarians and centenarians: A comprehensive functional assessment by the instruments of geriatric practiceJ Am Geriatr Soc1997451196-1202. 26. Ravaglia G, Forti P, Maioli F, Boschi F, Cicognani A, Bernardi M, Pratelli L, Pizzoferrato A, Porcu S, Gasbarrini G. Determinants of functional status in healthy Italian nonagenarians and centenarians: A comprehensive functional assessment by the instruments of geriatric practice. J Am Geriatr Soc 1997;45:1196–1202.
27.
Bischoff-Ferrari HAOrav EJDawson-Hughes B. Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and womenOsteoporos Int2008191307-1314. 27. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporos Int 2008;19:1307–1314.
28.
Villareal DTHolloszy JOKohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and menClin Endocrinol200053561-568. 28. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 2000;53:561–568.
29.
Kalman DS CCSwain MATorina GCShi Q. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy over- weight adultsCurr Ther Res200061435-442. 29. Kalman DS CC, Swain MA, Torina GC, Shi Q. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy over- weight adults. Curr Ther Res 2000;61:435–442.
30.
Villareal DTHolloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trialJAMA20042922243-2248. 30. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 2004;292:2243–2248.
31.
Kenny AMBoxer RSKleppinger ABrindisi JFeinn RBurleson JA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older womenJ Am Geriatr Soc2010581707-1714. 31. Kenny AM, Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc 2010;58:1707–1714.
32.
Jedrzejuk DMedras MMilewicz ADemissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin sensitivity and lipid metabolismAging Male20036151-156. 32. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 2003;6:151–156.
33.
Callies FFassnacht Mvan Vlijmen JCKoehler IHuebler DSeibel MJArlt WAllolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on body composition, serum leptin, bone turnover, and exercise capacityJ Clin Endocrinol Metab2001861968-1972. 33. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 2001;86:1968–1972.
34.
Flynn MAWeaver-Osterholtz DSharpe-Timms KLAllen SKrause G. Dehydroepiandrosterone replacement in aging humansJ Clin Endocrinol Metab1999841527-1533. 34. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999;84:1527–1533.
35.
Percheron GHogrel JYDenot-Ledunois SFayet GForette FBaulieu EEFardeau MMarini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: A double-blind placebo-controlled trialArch Int Med2003163720-727. 35. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: A double-blind placebo-controlled trial. Arch Int Med 2003;163:720–727.
36.
Igwebuike AIrving BABigelow MLShort KRMcConnell JPNair KS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal womenJ Clin Endocrinol Metab200893534-538. 36. Igwebuike A, Irving BA, Bigelow ML, Short KR, McConnell JP, Nair KS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab 2008;93:534–538.
37.
Rizzoli R. Management of the oldest old with osteoporosisEur Geriatr Med2010115-21. 37. Rizzoli R. Management of the oldest old with osteoporosis. Eur Geriatr Med 2010;1:15–21.
38.
Nawata HTanaka STanaka STakayanagi RSakai YYanase TIkuyama SHaji M. Aromatase in bone cell: Association with osteoporosis in postmenopausal womenJ Steroid Biochem Mol Biol199553165-174. 38. Nawata H, Tanaka S, Tanaka S, Takayanagi R, Sakai Y, Yanase T, Ikuyama S, Haji M. Aromatase in bone cell: Association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol 1995;53:165–174.
39.
Wang LWang YDWang WJZhu YLi DJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptorJ Mol Endocrinol200738467-479. 39. Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol 2007;38:467–479.
40.
Clarke BLEbeling PRJones JDWahner HWO'Fallon WMRiggs BLFitzpatrick LA. Predictors of bone mineral density in aging healthy men varies by skeletal siteCalcified Tiss Int200270137-145. 40. Clarke BL, Ebeling PR, Jones JD, Wahner HW, O'Fallon WM, Riggs BL, Fitzpatrick LA. Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcified Tiss Int 2002;70:137–145.
41.
Weiss EPShah KFontana LLambert CPHolloszy JOVillareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on boneAm J Clin Nutr2009891459-1467. 41. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr 2009;89:1459–1467.
42.
von Muhlen DLaughlin GAKritz-Silverstein DBergstrom JBettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: The DAWN trialOsteoporosis Int200819699-707. 42. von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: The DAWN trial. Osteoporosis Int 2008;19:699–707.
43.
Jankowski CMGozansky WSKittelson JMVan Pelt RESchwartz RSKohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogensJ Clin Endocrinol Metab2008934767-4773. 43. Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab 2008;93:4767–4773.
44.
Jankowski CMGozansky WSSchwartz RSDahl DJKittelson JMScott SMVan Pelt REKohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: A randomized, controlled trialJ Clin Endocrinol Metab2006912986-2993. 44. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: A randomized, controlled trial. J Clin Endocrinol Metab 2006;91:2986–2993.
45.
Labrie FDiamond PCusan LGomez JLBelanger ACandas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal womenJ Clin Endocrinol Metab1997823498-3505. 45. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498–3505.
46.
Sun YMao MSun LFeng YYang JShen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfateChinese Med J2002115402-404. 46. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chinese Med J 2002;115:402–404.
47.
Nair KSRizza RAO'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly menN Engl J Med20063551647-1659. 47. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647–1659.
48.
Berr CWancata JRitchie K. Prevalence of dementia in the elderly in EuropeEur Neuropsychopharmacol200515463-471. 48. Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 2005;15:463–471.
49.
Graham JERockwood KBeattie BLEastwood RGauthier STuokko HMcDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly populationLancet19973491793-1796. 49. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793–1796.
50.
Barnes DEYaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalenceLancet Neurol201110819-828. 50. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011;10:819–828.
51.
Lautenschlager NTCox KCyarto EV. The influence of exercise on brain aging and dementiaBiochim Biophys Acta20121822474-481. 51. Lautenschlager NT, Cox K, Cyarto EV. The influence of exercise on brain aging and dementia. Biochim Biophys Acta 2012;1822:474–481.
52.
Lu SFMo QHu SGarippa CSimon NG. Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activityJ Neurobiol200357163-71. 52. Lu SF, Mo Q, Hu S, Garippa C, Simon NG. Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol 2003;57:163–71.
53.
Suzuki MWright LSMarwah PLardy HASvendsen CN. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortexProc Natl Acad Sci USA20041013202-3207. 53. Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 2004;101:3202–3207.
54.
Lang POLapenna APitts DAspinall R. Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescenceEur Ger Med20101112-121. 54. Lang PO, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescence. Eur Ger Med 2010;1:112–121.
55.
Davis SRShah SMMcKenzie DPKulkarni JDavison SLBell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in womenJ Clin Endocrinol Metab200893801-808. 55. Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008;93:801–808.
56.
Valenti GFerrucci LLauretani FCeresini GBandinelli SLuci MCeda GMaggio MSchwartz RS. Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI StudyJ Endocrinol Invest200932766-772. 56. Valenti G, Ferrucci L, Lauretani F, Ceresini G, Bandinelli S, Luci M, Ceda G, Maggio M, Schwartz RS. Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI Study. J Endocrinol Invest 2009;32:766–772.
57.
Morrison MFRedei ETenHave TParmelee PBoyce AASinha PSKatz IR. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care populationBiol Psychiatry200047144-150. 57. Morrison MF, Redei E, TenHave T, Parmelee P, Boyce AA, Sinha PS, Katz IR. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol Psychiatry 2000;47:144–150.
58.
Barrett-Connor EEdelstein SL. A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: The Rancho Bernardo StudyJ Am Geriatr Soc199442420-423. 58. Barrett-Connor E, Edelstein SL. A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: The Rancho Bernardo Study. J Am Geriatr Soc 1994;42:420–423.
59.
Kritz-Silverstein Dvon Muhlen DLaughlin GABettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: The DHEA and Well-Ness (DAWN) TrialJ Am Geriatr Soc2008561292-1298. 59. Kritz-Silverstein D, von Muhlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: The DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56:1292–1298.
60.
van Niekerk JKHuppert FAHerbert J. Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementationPsychoneuroendocrinology200126591-612. 60. van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology 2001;26:591–612.
61.
Barnhart KTFreeman EGrisso JARader DJSammel MKapoor SNestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of lifeJ Clin Endocrinol Metab1999843896-3902. 61. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896–3902.
62.
Finckh ABerner ICAubry-Rozier BSo AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgiaJ Rheumatol2005321336-1340. 62. Finckh A, Berner IC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005;32:1336–1340.
63.
Wolf OTKudielka BMHellhammer DHHellhammer JKirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressorPsychoneuroendocrinology199823617-629. 63. Wolf OT, Kudielka BM, Hellhammer DH, Hellhammer J, Kirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology 1998;23:617–629.
64.
Yamada SAkishita MFukai SOgawa SYamaguchi KMatsuyama JKozaki KToba KOuchi Y. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairmentGeriatr Gerontol Int201010280-287. 64. Yamada S, Akishita M, Fukai S, Ogawa S, Yamaguchi K, Matsuyama J, Kozaki K, Toba K, Ouchi Y. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatr Gerontol Int 2010;10:280–287.
65.
Samaras NRossi GGiannakopoulos PGold G. Vascular depression. An age-related mood disorderEur Ger Med20104220-225. 65. Samaras N, Rossi G, Giannakopoulos P, Gold G. Vascular depression. An age-related mood disorder. Eur Ger Med 2010;4:220–225.
66.
Steffens DC. A multiplicity of approaches to characterize geriatric depression and its outcomesCurr Opin Psychiatry200922522-526. 66. Steffens DC. A multiplicity of approaches to characterize geriatric depression and its outcomes. Curr Opin Psychiatry 2009;22:522–526.
67.
Robichaud MDebonnel G. Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroidsJ Endocrinol200418211-21. 67. Robichaud M, Debonnel G. Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroids. J Endocrinol 2004;182:11–21.
68.
Barrett-Connor Evon Muhlen DLaughlin GAKripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo StudyJ Am Geriatr Soc199947685-691. 68. Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685–691.
69.
Michael AJenaway APaykel ESHerbert J. Altered salivary dehydroepiandrosterone levels in major depression in adultsBiol Psychiatry200048989-995. 69. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989–995.
70.
Schmidt PJDaly RCBloch MSmith MJDanaceau MASt Clair LSMurphy JHHaq NRubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depressionArch Gen Psychiatry200562154-162. 70. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154–162.
71.
Wolkowitz OMReus VIRoberts EManfredi FChan TRaum WJOrmiston SJohnson RCanick JBrizendine LWeingartner H. Dehydroepiandrosterone (DHEA) treatment of depressionBiol Psychiatry199741311-318. 71. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311–318.
72.
Wolkowitz OMReus VIKeebler A et al. Double-blind treatment of major depression with dehydroepiandrosteroneAm J Psychiatry1999156646-649. 72. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646–649.
73.
Strous RDMaayan RLapidus RStryjer RLustig MKotler MWeizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophreniaArch Gen Psychiatry200360133-141. 73. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133–141.
74.
Bloch MSchmidt PJDanaceau MAAdams LFRubinow DR. Dehydroepiandrosterone treatment of midlife dysthymiaBiol Psychiatry1999451533-1541. 74. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533–1541.
75.
Samaras NChevalley TSamaras DGold G. Older patients in the emergency department: A reviewAnn Emerg Med201056261-269. 75. Samaras N, Chevalley T, Samaras D, Gold G. Older patients in the emergency department: A review. Ann Emerg Med 2010;56:261–269.
76.
Srinivasan MIrving BADhatariya KKlaus KAHartman SJMcConnell JPNair KS. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal womenJ Clin Endocrinol Metab200994761-764. 76. Srinivasan M, Irving BA, Dhatariya K, Klaus KA, Hartman SJ, McConnell JP, Nair KS. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. J Clin Endocrinol Metab 2009;94:761–764.
77.
Rice SPAgarwal NBolusani HNewcombe RScanlon MFLudgate MRees DA. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: A randomized crossover trialJ Clin Endocrinol Metab2009941966-1972. 77. Rice SP, Agarwal N, Bolusani H, Newcombe R, Scanlon MF, Ludgate M, Rees DA. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: A randomized crossover trial. J Clin Endocrinol Metab 2009;94:1966–1972.
78.
Casson PRSantoro NElkind-Hirsch KCarson SAHornsby PJAbraham GBuster JE. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: A six-month trialFertil Steril199870107-110. 78. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster JE. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: A six-month trial. Fertil Steril 1998;70:107–110.
79.
Diamond PCusan LGomez JLBelanger ALabrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal womenJ Endocrinol1996150SupplS43-S50. 79. Diamond P, Cusan L, Gomez JL, Belanger A, Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol 1996;150(Suppl):S43–S50.
80.
Srinivasan MIrving BAFrye RLO'Brien PHartman SJMcConnell JPNair KS. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly menJ Clin Endocrinol Metab2010951617-1625. 80. Srinivasan M, Irving BA, Frye RL, O'Brien P, Hartman SJ, McConnell JP, Nair KS. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men. J Clin Endocrinol Metab 2010;95:1617–1625.
81.
Lasco AFrisina NMorabito NGaudio AMorini ETrifiletti ABasile GNicita-Mauro VCucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal womenEur J Endocrinol2001145457-461. 81. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V, Cucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457–461.
82.
Bell RJDavison SLPapalia MAMcKenzie DPDavis SR. Endogenous androgen levels and cardiovascular risk profile in women across the adult life spanMenopause200714630-638. 82. Bell RJ, Davison SL, Papalia MA, McKenzie DP, Davis SR. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 2007;14:630–638.
83.
Shufelt CBretsky PAlmeida CMJohnson BDShaw LJAzziz RBraunstein GDPepine CJBittner VVido DAStanczyk FZBairey Merz CN. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)J Clin Endocrinol Metab2010954985-4992. 83. Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, Azziz R, Braunstein GD, Pepine CJ, Bittner V, Vido DA, Stanczyk FZ, Bairey Merz CN. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985–4992.
84.
Christiansen JJAndersen NHSørensen KEPedersen EMBennett PAndersen MChristiansen JSJørgensen JOGravholt CH. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen statusClin Endocrinol200766426-433. 84. Christiansen JJ, Andersen NH, Sørensen KE, Pedersen EM, Bennett P, Andersen M, Christiansen JS, Jørgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol 2007;66:426–433.
85.
Panjari MBell RJJane FAdams JMorrow CDavis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal womenMaturitas200963240-245. 85. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240–245.
86.
Cleary MPZisk JF. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker ratsInt J Obes198610193-204. 86. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes 1986;10:193–204.
87.
Mohan PFIhnen JSLevin BECleary MP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesityJ Nutr19901201103-1114. 87. Mohan PF, Ihnen JS, Levin BE, Cleary MP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr 1990;120:1103–1114.
88.
Hansen PAHan DHNolte LAChen MHolloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat dietAm J Physiol1997273R1704-R1708. 88. Hansen PA, Han DH, Nolte LA, Chen M, Holloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol 1997;273:R1704–R1708.
89.
Golden SHDobs ASVaidya DSzklo MGapstur SKopp PLiu KOuyang P. Endogenous sex hormones and glucose tolerance status in postmenopausal womenJ Clin Endocrinol Metab2007921289-1295. 89. Golden SH, Dobs AS, Vaidya D, Szklo M, Gapstur S, Kopp P, Liu K, Ouyang P. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007;92:1289–1295.
90.
Barrett-Connor EFerrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo StudyJ Clin Endocrinol Metab19968159-64. 90. Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab 1996;81:59–64.
91.
Dhatariya KBigelow MLNair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal womenDiabetes200554765-769. 91. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005;54:765–769.
92.
Gebre-Medhin GHusebye ESMallmin HHelström LBerne CKarlsson FAKämpe O. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's diseaseClin Endocrinol200052775-780. 92. Gebre-Medhin G, Husebye ES, Mallmin H, Helström L, Berne C, Karlsson FA, Kämpe O. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol 2000;52:775–780.
93.
Hayashi TEsaki TMuto EKano HAsai YThakur NKSumi DJayachandran MIguchi A. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: The possible role of nitric oxideArterioscler Thromb Vasc Biol200020782-792. 93. Hayashi T, Esaki T, Muto E, Kano H, Asai Y, Thakur NK, Sumi D, Jayachandran M, Iguchi A. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: The possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000;20:782–792.
94.
Gordon GBBush DEWeisman HFReduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injuryJ Clin Invest198882712-720. 94. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 1988;82:712–720.
95.
Wang LHao QWang YDWang WJLi DJ. Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cellsAtherosclerosis201121447-57. 95. Wang L, Hao Q, Wang YD, Wang WJ, Li DJ. Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cells. Atherosclerosis 2011;214:47–57.
96.
Eich DMNestler JEJohnson DEDworkin GHKo DWechsler ASHess ML. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantationCirculation199387261-269. 96. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 1993;87:261–269.
97.
Samaras NSamaras DLang POForster APichard CFrangos EMeyer PA view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes? Maturitas201374213-219. 97. Samaras N, Samaras D, Lang PO, Forster A, Pichard C, Frangos E, Meyer P. A view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes? Maturitas 2013;74:213–219.
98.
Feldman HAJohannes CBAraujo ABMohr BALongcope CMcKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: Prospective results from the Massachusetts Male Aging StudyAm J Epidemiol200115379-89. 98. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: Prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 2001;153:79–89.
99.
Yoshida SAihara KAzuma HUemoto RSumitomo-Ueda YYagi SIkeda YIwase TNishio SKawano HMiki JYamada HHirata YAkaike MSata MMatsumoto T. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial functionAtherosclerosis2010212310-315. 99. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, Ikeda Y, Iwase T, Nishio S, Kawano H, Miki J, Yamada H, Hirata Y, Akaike M, Sata M, Matsumoto T. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis 2010;212:310–315.
100.
Herrington DM. Dehydroepiandrosterone and coronary atherosclerosisAnn NY Acad Sci1995774271-280. 100. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci 1995;774:271–280.
101.
Herrington DMNanjee NAchuff SCCameron DEDobbs BBaughman KL. Dehydroepiandrosterone and cardiac allograft vasculopathyJ Heart Lung Transplant19961588-93. 101. Herrington DM, Nanjee N, Achuff SC, Cameron DE, Dobbs B, Baughman KL. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant 1996;15:88–93.
102.
Nakamura SYoshimura MNakayama MIto TMizuno YHarada ESakamoto TSaito YNakao KYasue HOgawa H. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heartCirculation20041101787-1793. 102. Nakamura S, Yoshimura M, Nakayama M, Ito T, Mizuno Y, Harada E, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation 2004;110:1787–1793.
103.
Jankowska EABiel BMajda JSzklarska ALopuszanska MMedras MAnker SDBanasiak WPoole-Wilson PAPonikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survivalCirculation20061141829-1837. 103. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829–1837.
104.
Barrett-Connor EGoodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal womenThe Rancho Bernardo Study. Circulation1995911757-1760. 104. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995;91:1757–1760.
105.
Barrett-Connor EKhaw KTYen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular diseaseN Engl J Med19863151519-1524. 105. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986;315:1519–1524.
106.
Hyde ZFlicker LHankey GJAlmeida OPMcCaul KAChubb SAYeap BB. Prevalence and predictors of sexual problems in men aged 75–95 years: A population-based studyJ Sex Med20129442-453. 106. Hyde Z, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB. Prevalence and predictors of sexual problems in men aged 75–95 years: A population-based study. J Sex Med 2012;9:442–453.
107.
Basar MMAydin GMert HCKeles ICaglayan OOrkun SBatislam E. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile FunctionUrology200566597-601. 107. Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S, Batislam E. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology 2005;66:597–601.
108.
Alexopoulou OJamart JMaiter DHermans MPDe Hertogh RDe Nayer PBuysschaert M. Erectile dysfunction and lower androgenicity in type 1 diabetic patientsDiabetes Metab200127329-336. 108. Alexopoulou O, Jamart J, Maiter D, Hermans MP, De Hertogh R, De Nayer P, Buysschaert M. Erectile dysfunction and lower androgenicity in type 1 diabetic patients. Diabetes Metab 2001;27:329–336.
109.
Feldman HAGoldstein IHatzichristou DGKrane RJMcKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging StudyJ Urol199415154-61. 109. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
110.
Reiter WJPycha ASchatzl GKlingler HCMärk IAuterith AMarberger M. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunctionUrology200055755-758. 110. Reiter WJ, Pycha A, Schatzl G, Klingler HC, Märk I, Auterith A, Marberger M. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology 2000;55:755–758.
111.
Reiter WJPycha ASchatzl GPokorny AGruber DMHuber JCMarberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomized, placebo-controlled studyUrology199953590-594. 111. Reiter WJ, Pycha A, Schatzl G, Pokorny A, Gruber DM, Huber JC, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomized, placebo-controlled study. Urology 1999;53:590–594.
112.
Morales ABlack AEmerson LBarkin JKuzmarov IDay A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiencyAging Male200912104-112. 112. Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male 2009;12:104–112.
113.
Reiter WJSchatzl GMark IZeiner APycha AMarberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologiesUrol Res200129278-281. 113. Reiter WJ, Schatzl G, Mark I, Zeiner A, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 2001;29:278–281.
114.
Davis SRDavison SLDonath SBell RJ. Circulating androgen levels and self-reported sexual function in womenJAMA200529491-96. 114. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91–96.
115.
Genazzani ARStomati MValentino VPluchino NPot ECasarosa EMerlini SGiannini ALuisi M. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexualityClimacteric201114661-668. 115. Genazzani AR, Stomati M, Valentino V, Pluchino N, Pot E, Casarosa E, Merlini S, Giannini A, Luisi M. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661–668.
116.
Arlt WCallies Fvan Vlijmen JCKoehler IReincke MBidlingmaier MHuebler DOettel MErnst MSchulte HMAllolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiencyN Engl J Med19993411013-1020. 116. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013–1020.
117.
Munarriz RTalakoub LFlaherty EGioia MHoag LKim NNTraish AGoldstein IGuay ASpark R. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: Androgen and questionnaire resultsJ Sex Marital Ther200228Suppl 1165-173. 117. Munarriz R, Talakoub L, Flaherty E, Gioia M, Hoag L, Kim NN, Traish A, Goldstein I, Guay A, Spark R. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: Androgen and questionnaire results. J Sex Marital Ther 2002;28(Suppl 1):165–173.
118.
Labrie FArcher DBouchard CFortier MCusan LGomez JLGirard GBaron MAyotte NMoreau MDubé RCôté ILabrie CLavoie LBerger LGilbert LMartel CBalser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenMenopause200916923-931. 118. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–931.
119.
Panjari MBell RJJane FWolfe RAdams JMorrow CDavis SR. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libidoJ Sex Med200962579-2590. 119. Panjari M, Bell RJ, Jane F, Wolfe R, Adams J, Morrow C, Davis SR. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579–2590.
120.
Stomati MMonteleone PCasarosa EQuirici BPuccetti SBernardi FGenazzani ADRovati LLuisi MGenazzani AR. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopauseGynecolog Endocrinol200014342-363. 120. Stomati M, Monteleone P, Casarosa E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecolog Endocrinol 2000;14:342–363.
121.
Labrie FArcher DBouchard CFortier MCusan LGomez JLGirard GBaron MAyotte NMoreau MDubé RCôté ILabrie CLavoie LBerger LGilbert LMartel CBalser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyMenopause200916907-922. 121. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–922.
122.
Labrie FLuu-The VBélanger ALin SXSimard JPelletier GLabrie C. Is dehydroepiandrosterone a hormone?J Endocrinol2005187169-196. 122. Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187:169–196.
123.
Arlt W. The approach to the adult with newly diagnosed adrenal insufficiencyJ Clin Endocrinol Metab2009941059-1067. 123. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab 2009;94:1059–1067.
124.
Labrie FCusan LGomez JLMartel CBérubé RBélanger PChaussade VDeloche CLeclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEAJ Steroid Biochem Mol Biol20081101-9. 124. Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Chaussade V, Deloche C, Leclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1–9.
125.
Sulcová JHill MHampl RMasek ZNovácek ACeska RStárka L. Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in menPhysiol Res200049685-693. 125. Sulcová J, Hill M, Hampl R, Masek Z, Novácek A, Ceska R, Stárka L. Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in men. Physiol Res 2000;49:685–693.
126.
Arnold JT. DHEA metabolism in prostate: For better or worse?Mol Cell Endocrinol200930183-88. 126. Arnold JT. DHEA metabolism in prostate: For better or worse? Mol Cell Endocrinol 2009;301:83–88.
127.
Stanway SJPurohit AWoo LWSufi SVigushin DWard RWilson RHStanczyk FZDobbs NKulinskaya EElliott MPotter BVReed MJCoombes RC. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitorClin Cancer Res2006121585-1592. 127. Stanway SJ, Purohit A, Woo LW, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BV, Reed MJ, Coombes RC. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585–1592.
128.
Schwartz AGPashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevityAgeing Res Rev20043171-187. 128. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004;3:171–187.
129.
Schwartz AGPashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogsJ Cell Biochem Supplement199522210-217. 129. Schwartz AG, Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Supplement 1995;22:210–217.
Information & Authors
Information
Published In
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published online: 14 August 2013
Published in print: August 2013
Published ahead of production: 7 May 2013
Accepted: 6 May 2013
Received: 13 March 2013
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.